Paul K. Wallace

Paul K. Wallace

Auto-generated profile, based on publicly available information

Paul K. Wallace

Department of Microbiology, HB7556, Dartmouth Medical School, 1 Medical Center Drive, Lebanon, NH 03756, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2008 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
PWPaul K. Wallace
Paul K. Wallace
JTJoseph D. Tario
Joseph D. Tario
JFJan L. Fisher
Jan L. Fisher
SWStephen S. Wallace
Stephen S. Wallace
MEMarc S. Ernstoff
Marc S. Ernstoff
KMKatharine A. Muirhead
Katharine A. Muirhead
Cell‐tracking reagents such as the green‐fluorescent protein labeling dye CFSE and the red‐fluorescent lipophilic membrane dye PKH26 are commonly used to monitor cell proliferation by flow cytometry in heterogeneous cell populations responding to immune stimuli. Both reagents stain cells with a bright homogeneous fluorescence, which is partitioned between daughter cells during each cell division. Because daughter cell fluorescence intensities are approximately halved after each division, the intensity of a cell relative to its intensity at the time of staining provides information about how many divisions it has undergone. Knowing how many rounds of division have occurred and the relative number of cells in each daughter generation, one can back‐calculate the number of cells in the original population (i.e., cells present at the time of stimulus) that went on to respond by proliferating. Using this information, the precursor cell frequencies and extent of expansion to a specific antigen or mitogen of interest can be calculated. Concurrently, the phenotype of the cells can be determined, as well as their ability to bind antigen or synthesize cytokines, providing more detailed characterization of all cells responding to the antigen, not just effector cells. In multiparameter flow cytometric experiments to simultaneously analyze antigen‐specific tetramer binding, cytokine production and T‐cell proliferation, we found that only approximately half of the cells that exhibited specific binding to influenza tetramer also proliferated, as measured by dye dilution, and synthesized IFNγ in response to antigen. We expect the advent of new cell tracking dyes emitting from the violet to the near infrared combined with the increasing number of lasers and detectors on contemporary flow cytometers to further expand the usefulness of this approach to characterization of complex antigen‐driven immunological responses. © 2008 International Society for Advancement of Cytometry

15 November 2010
Verified
Book Chapter
Closed access
PDF file
JTJoseph D. Tario
Joseph D. Tario
KMKatharine A. Muirhead
Katharine A. Muirhead
DPDalin Pan
Dalin Pan
MMMark E. Munson
Mark E. Munson
PWPaul K. Wallace
Paul K. Wallace

1 March 2001 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
PWPaul K Wallace
Paul K Wallace
GYGrant R Yeaman
Grant R Yeaman
KJKristy Johnson
Kristy Johnson
JCJane E Collins
Jane E Collins
PGPaul M Guyre
Paul M Guyre
CWCharles R Wira
Charles R Wira

1 February 2001 in Journal of Immunological Methods
Verified
Journal Article
Closed access
PWPaul K Wallace
Paul K Wallace
KTKwong Y Tsang
Kwong Y Tsang
JGJoel Goldstein
Joel Goldstein
Pierpaolo CorrealePierpaolo Correale
Pierpaolo Correale
TJTodd M Jarry
Todd M Jarry
MFMichael W Fanger
Michael W Fanger

13 December 2012 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
JJJoseph D. Tario Jr.
Joseph D. Tario Jr.
KHKristen Humphrey
Kristen Humphrey
ABAndrew D. Bantly
Andrew D. Bantly
KMKatharine A. Muirhead
Katharine A. Muirhead
JMJonni S. Moore
Jonni S. Moore
PWPaul K. Wallace
Paul K. Wallace
Successful use of cell tracking dyes to monitor immune cell function and proliferation involves several critical steps. We describe...

10 August 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MPMarcelo C. Pasquini
Marcelo C. Pasquini
PWPaul K. Wallace
Paul K. Wallace
BLBrent Logan
Brent Logan
MKManmeet Kaur
Manmeet Kaur
JTJoseph D. Tario
Joseph D. Tario
THTheresa Hahn
Theresa Hahn
PURPOSE: Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on a three-arm randomized control trial (Blood and Marrow Transplants Clinical Trials Network 0702 Stem Cell Transplant for Myeloma in Combination of Novel Agents [STaMINA]; ClinicalTrials.gov identifier: NCT01109004 ). METHODS: Four hundred and thirty-five patients consented to the MRD panel, which included 10 monoclonal antibodies measured via six-color MFC. MRD was measured at baseline/preautologous hematopoietic cell transplant (BL/preAutoHCT), premaintenance (PM), and 1 year (Y1) after AutoHCT with a sensitivity of 10–5 to 10–6. The primary objective was to assess MRD-negative (MRDneg) at 1 year after AutoHCT and progression-free survival and overall survival (PFS/OS). RESULTS: Similar to the STaMINA results, at a median follow-up of 70 months, there was no significant difference in PFS/OS by treatment arm in the PRIMeR patients. MRDneg at all three time points was associated with significantly improved PFS, and MRDneg at Y1 had significantly longer OS. Multivariate analysis of PFS, adjusting for disease risk and treatment arm, demonstrated hazard ratios (HRs) in MRD-positive patients compared with MRDneg patients at BL, PM, and Y1 of 1.55 ( P = .0074), 1.83 ( P = .0007), and 3.61 ( P < .0001), respectively. Corresponding HRs for OS were 1.19 ( P = .48), 0.88 ( P = .68), and 3.36 ( P < .001). Patients with sustained MRDneg or who converted to MRDneg by Y1 had similar PFS/OS. CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.